BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Australian Drug Developer, Hunter Immunology Limited, Set to List on ASX


3/30/2012 10:02:04 AM

SYDNEY Australia, 30 March 2012: Private drug developer Hunter Immunology Limited has announced that it has completed its merger with ASX-listed company Probiomics Limited (ASX: PCC). The merged entity is due to relist on the Australian Securities Exchange (ASX) on Wednesday 4 April 2012.

The business will trade as Probiomics (ASX: PCC) and be renamed as Bioxyne (ASX: BXN) in coming weeks. On the first day of relisting it will have an estimated market cap of AU$33 million with 149.9 million shares. In the lead up to the merger and relisting, Probiomics raised $2.4 million at $0.22 cents following a 1:20 share consolidation. The cash raised will provide funds to complete the Phase IIb trial and engage in negotiations with potential partners.

The Company’s core asset is a new drug in development to treat chronic obstructive pulmonary disease (COPD). A Phase II b clinical trial of the drug in COPD sufferers will be released mid 2012. A Phase IIa study showed it prevented hospitalisation rates by 90 per cent. For further information please contact:

At the Company

David Radford

Chief Executive Officer

Tel: : +61 (0) 407-218-922

Email: info@hunterimmunology.com

Media contacts

College Hill

Sue Charles – (UK) +44 (0)7968 726585 (AUS) +61 (0)466 924218

Gemma Howe – (UK) +44 (0)20 7866 7860

Email: hunterimmunology@collegehill.com

City Public Relations

Tim Allerton or Andrew Geddes (AUS) +(02) 9267 4511



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES